Overview
Lactobacillus reuteri (reclassified as Limosilactobacillus reuteri) is one of the most thoroughly studied probiotic species in human health research. Named after German microbiologist Gerhard Reuter, who first isolated it from human fecal samples in 1962, L. reuteri is notable for being one of the few Lactobacillus species that has co-evolved with humans and other vertebrates over millions of years, establishing itself as a true commensal of the mammalian gastrointestinal tract.[1]
Unlike many probiotic species that are primarily derived from fermented foods, L. reuteri is a natural inhabitant of the human gut, oral cavity, and vaginal tract. However, research suggests that its prevalence in modern Western populations has declined significantly compared to traditional societies, possibly due to dietary changes, widespread antibiotic use, and modern hygiene practices. This evolutionary relationship may partly explain why L. reuteri demonstrates such a broad range of health benefits across multiple body systems.
Classification
L. reuteri is a Gram-positive, rod-shaped, facultatively anaerobic bacterium belonging to the family Lactobacillaceae. It can grow under both aerobic and anaerobic conditions, though it thrives in low-oxygen environments typical of the gastrointestinal tract. The species was reclassified in 2020 from the genus Lactobacillus to the newly created genus Limosilactobacillus, though the former name remains widely used in clinical literature and product labeling.
The bacterium measures approximately 0.7-1.0 x 2.0-3.0 micrometers and typically appears as single cells or short chains. It is catalase-negative and produces both lactic acid and acetic acid as primary fermentation products, classifying it as an obligately heterofermentative lactic acid bacterium.
Key Characteristics
Reuterin Production
Perhaps the most distinctive feature of L. reuteri is its ability to produce reuterin (3-hydroxypropionaldehyde), a potent broad-spectrum antimicrobial compound generated from glycerol metabolism. Reuterin is effective against Gram-positive bacteria, Gram-negative bacteria, fungi, and protozoa, giving L. reuteri a competitive advantage in the gut ecosystem and contributing to its pathogen-suppressing capabilities.[1]
Reuterin may inhibit the growth of harmful organisms such as Escherichia coli, Salmonella, Shigella, Clostridium difficile, and Helicobacter pylori, providing a molecular basis for many of the clinical benefits observed with L. reuteri supplementation.
Histamine Production
L. reuteri possesses the enzyme histidine decarboxylase, which converts the amino acid L-histidine into histamine within the gut lumen. This microbially produced histamine acts through H2 receptors on intestinal epithelial cells to suppress pro-inflammatory TNF production via a protein kinase A (PKA)-dependent mechanism. This pathway represents one of the key immunomodulatory mechanisms through which L. reuteri may exert anti-inflammatory effects.[1]
Clinical Evidence
Infant Colic
The strongest clinical evidence for L. reuteri comes from its use in infant colic, particularly with the DSM 17938 strain. A pivotal randomized controlled trial demonstrated that supplementation reduced crying time in breastfed colicky infants from an average of 370 minutes per day to just 35 minutes per day after 21 days of treatment, with a 95% treatment response rate compared to 7% in the placebo group.[2]
However, results have been more mixed in broader populations. A community-based trial including both breastfed and formula-fed infants found no significant overall benefit, though breastfed infants showed a positive trend.[3] Meta-analyses generally support efficacy in breastfed infants, with more variable results in formula-fed infants. The mechanism may involve modulation of gut microbial composition and reduction of intestinal inflammation through reuterin production and immune pathway regulation.
Bone Health
A landmark randomized controlled trial in elderly women (aged 75-80) with low bone mineral density demonstrated that L. reuteri ATCC PTA 6475 reduced tibial bone loss by 75% over 12 months compared to placebo. Total volumetric bone mineral density loss was -0.83% in the treatment group versus -3.32% in the placebo group. This study provided the first clinical evidence that a probiotic could meaningfully reduce age-related bone loss in humans.[4]
The proposed mechanism involves modulation of systemic and local bone marrow inflammation, with L. reuteri suppressing TNF-alpha and other osteoclastogenic cytokines through its histamine-mediated anti-inflammatory pathway.
Vitamin D Metabolism
A post hoc analysis of a randomized controlled trial revealed that L. reuteri NCIMB 30242 increased circulating 25-hydroxyvitamin D levels by 25.5% over 9 weeks, making it the first probiotic demonstrated to raise serum vitamin D. This finding suggests a potential role in supporting vitamin D status, particularly in populations at risk of deficiency.[5]
Oral Health
Clinical trials have demonstrated benefits of L. reuteri for periodontal health. A randomized controlled trial showed significant reductions in gingival bleeding index and plaque index after just 14 days of probiotic lozenge use, with meaningful improvements in gingivitis scores.[6] The mechanism likely involves competitive exclusion of periodontopathic bacteria and local reuterin-mediated antimicrobial activity in the oral cavity.
Mechanisms of Action
Immune Modulation
L. reuteri modulates host immunity through several interconnected pathways:[1]
- Histamine-mediated TNF suppression: Converts L-histidine to histamine, which activates H2 receptors on epithelial cells to suppress TNF production via PKA signaling
- Dendritic cell programming: Promotes differentiation of regulatory T cells through effects on dendritic cell maturation
- IL-10 upregulation: Increases production of the anti-inflammatory cytokine IL-10, helping to maintain immune homeostasis
- Mucosal IgA enhancement: Supports secretory IgA production at mucosal surfaces, strengthening first-line immune defense
Antimicrobial Activity
The reuterin system provides broad-spectrum antimicrobial activity through multiple mechanisms:
- Direct inhibition: Reuterin damages bacterial DNA and protein synthesis
- Biofilm disruption: Interferes with quorum sensing and biofilm formation in pathogenic species
- Competitive exclusion: Occupies mucosal adhesion sites, preventing pathogen colonization
- Acid production: Lactic acid and acetic acid production lowers local pH, inhibiting pH-sensitive pathogens
Gut-Brain Axis Signaling
Emerging preclinical research suggests that L. reuteri may influence the gut-brain axis through vagus nerve signaling. Animal studies have demonstrated effects on social behavior, stress response, and oxytocin levels, though human clinical evidence for neurological benefits remains limited and preliminary.
Ecological Role
L. reuteri occupies a unique ecological niche as a true vertebrate commensal. Its heterofermentative metabolism produces both lactic acid and acetic acid, contributing to the acidification of the gut environment. Through reuterin production, it helps maintain microbial balance by suppressing the overgrowth of potentially harmful organisms. The bacterium's ability to adhere to intestinal epithelial cells and mucus allows it to form stable biofilm-like communities on the mucosal surface.[1]
The species demonstrates host-adapted lineages, with human-derived strains showing genetic adaptations distinct from those isolated from other mammals, including specific adhesin genes and metabolic capabilities tailored to the human gastrointestinal environment.
Safety Profile
L. reuteri has an excellent safety record supported by decades of clinical use:[1]
- GRAS status: Generally Recognized As Safe by the U.S. Food and Drug Administration
- Infant safety: Extensively studied in neonates and infants, including premature infants, with no serious adverse events attributable to the probiotic
- Adult tolerance: Well tolerated across clinical trials with adverse event rates comparable to placebo
- No antibiotic resistance transfer risk: The DSM 17938 strain was specifically developed by removing transferable antibiotic resistance plasmids from the parent strain ATCC 55730
Populations Requiring Caution
- Severely immunocompromised individuals
- Patients with central venous catheters or other indwelling medical devices
- Individuals with short bowel syndrome or other conditions affecting intestinal barrier integrity
- Those taking immunosuppressive medications (consult healthcare provider)
Clinical Applications
Optimal Candidates
- Breastfed infants with colic (strongest evidence)
- Elderly women with low bone mineral density
- Individuals with gingivitis or periodontal disease
- Patients seeking immune support
- Those with suboptimal vitamin D status
Dosing
- Infant colic: 1x10^8 CFU/day (DSM 17938) for a minimum of 21 days
- Bone health: 1x10^10 CFU/day (ATCC PTA 6475) for 12 months
- Oral health: Probiotic lozenges containing 1x10^8 CFU twice daily
- General supplementation: 1x10^8 to 1x10^10 CFU/day depending on indication
Natural Sources
While L. reuteri is primarily obtained through supplementation, it can also be found in certain fermented foods, though typically at lower concentrations than clinical doses:
- Sourdough bread (as a fermentation organism)
- Some traditionally fermented dairy products
- Certain fermented meat products
The decline of L. reuteri in modern populations has been attributed to reduced consumption of traditionally fermented foods, increased antibiotic exposure, and dietary shifts away from fiber-rich whole foods.
Relationship to Other Probiotics
L. reuteri is often used alongside other probiotic species for synergistic effects. It complements Lactobacillus rhamnosus in multi-strain probiotic formulations, with each species contributing distinct mechanisms of action. While L. rhamnosus GG excels at mucosal adhesion and epithelial barrier support, L. reuteri provides unique antimicrobial activity through reuterin production and distinctive immunomodulatory effects via histamine signaling.
For a comprehensive overview of probiotic bacteria and their clinical applications, see our guide to probiotic bacteria.
As with any probiotic supplement, it is advisable to consult a healthcare professional before starting L. reuteri, particularly for infants, elderly individuals, or those with underlying health conditions.